Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
TEL AVIV, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2025 Healthy Future Report, outlining performance against its sustain
Blackstone's $400 Million Bet on Teva: What Does the Smart Money Know That Most Investors Don't?
04:44am, Thursday, 30'th Apr 2026
A significant financing deal with Blackstone underscores that the Teva of today isn't the Teva of the past.
Teva Pharmaceuticals CEO on acquiring Emalex Biosciences, drug portfolio
02:22pm, Wednesday, 29'th Apr 2026
Teva Pharmaceuticals CEO Richard Francis joins 'Money Movers' to discuss the company's latest acquisition of Emalex Biosciences, their latest drug offerings, and more.
Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan
01:52pm, Wednesday, 29'th Apr 2026
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), on Wednesday agreed to acquire Emalex Biosciences, including its lead asset, ecopipam.
Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say
12:01pm, Wednesday, 29'th Apr 2026
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of it
Markets Move Lower as FOMC Anticipation Grows
11:57am, Wednesday, 29'th Apr 2026
Stocks are trading lower as tech and heavy anticipation surrounding today's Fed meeting and Powell speech
Teva Pharmaceutical beats first-quarter profit estimates on branded drugs demand
07:05am, Wednesday, 29'th Apr 2026
Teva Pharmaceutical Industries beat Wall Street estimates for first-quarter profit on Wednesday, helped by sales of its branded medicines.
Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution
07:00am, Wednesday, 29'th Apr 2026
For an accessible version of this Press Release, please visit www.tevapharm.com
PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (“Emalex�
Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.
09:43pm, Monday, 27'th Apr 2026
Collectively, analysts tracking the stock expect declines in both revenue and profitability. The company continues to effect a major pivot in its business.
AE Wealth Management LLC Cuts Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA
03:09am, Tuesday, 21'st Apr 2026
AE Wealth Management LLC trimmed its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 41.6% in the undefined quarter, according to the company in its most recent disclosure wi
3 Catalysts That Could Send Teva Stock to $40 and Beyond
04:44am, Saturday, 18'th Apr 2026
FDA approval of long-acting schizophrenia drug olanzapine could be Teva's biggest near-term catalyst. Teva's specialty drugs continue to gain momentum.
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
08:00am, Wednesday, 15'th Apr 2026
PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launc
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
08:00am, Tuesday, 14'th Apr 2026
Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities Supplemental funding helps 11 free & char
Teva: The Market Is Pricing The Past, Not The Pipeline - Initiating Buy
08:52pm, Monday, 13'th Apr 2026
Teva Pharmaceuticals is undergoing a strategic shift from generics to specialty branded medicines, complex generics, biosimilars, and innovation-led pipeline expansion. TEVA's key growth drivers inclu
